Search research articles
Contact Us
Filters
Showing results (21-30 of 329) with videos related to
Page
of 33
Sort By:
Pharmacology Research & Perspectives
|
August 7, 2019
Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successes
Ann G Hayes, David J Nutt
Journal of Psychopharmacology (Oxford, England)
|
July 29, 2010
What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology
David J Nutt, Celia L Feetam
Journal of Psychopharmacology (Oxford, England)
|
March 29, 2014
Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs)
A Richard Green, David J Nutt
The Journal of Clinical Psychiatry
|
January 20, 2004
Structural and functional brain changes in posttraumatic stress disorder
David J Nutt, Andrea L Malizia
Journal of Psychopharmacology (Oxford, England)
|
August 2, 2013
Anhedonia revisited: is there a role for dopamine-targeting drugs for depression?
Spilios V Argyropoulos, David J Nutt
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
June 22, 2014
Where now for schizophrenia research?
David J Nutt, Anna C Need
CNS Spectrums
|
September 30, 2006
Understanding the neurobiology of comorbidity in anxiety disorders
David J Nutt, Dan J Stein
Pharmacology, Biochemistry, and Behavior
|
May 20, 2008
GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety?
Jayne E Bailey, David J Nutt
Depression and Anxiety
|
November 23, 2006
Role of GABA in anxiety and depression
Allan V Kalueff, David J Nutt
European Addiction Research
|
September 25, 2024
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction
Ioanna A Vamvakopoulou, David J Nutt
Page
of 33
Search research articles
Search
Showing results (21-30 of 329) with videos related to
Sort By:
Page
of 33
Pharmacology Research & Perspectives
|
August 7, 2019
Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successes
Ann G Hayes, David J Nutt
Journal of Psychopharmacology (Oxford, England)
|
July 29, 2010
What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology
David J Nutt, Celia L Feetam
Journal of Psychopharmacology (Oxford, England)
|
March 29, 2014
Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs)
A Richard Green, David J Nutt
The Journal of Clinical Psychiatry
|
January 20, 2004
Structural and functional brain changes in posttraumatic stress disorder
David J Nutt, Andrea L Malizia
Journal of Psychopharmacology (Oxford, England)
|
August 2, 2013
Anhedonia revisited: is there a role for dopamine-targeting drugs for depression?
Spilios V Argyropoulos, David J Nutt
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
June 22, 2014
Where now for schizophrenia research?
David J Nutt, Anna C Need
CNS Spectrums
|
September 30, 2006
Understanding the neurobiology of comorbidity in anxiety disorders
David J Nutt, Dan J Stein
Pharmacology, Biochemistry, and Behavior
|
May 20, 2008
GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety?
Jayne E Bailey, David J Nutt
Depression and Anxiety
|
November 23, 2006
Role of GABA in anxiety and depression
Allan V Kalueff, David J Nutt
European Addiction Research
|
September 25, 2024
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction
Ioanna A Vamvakopoulou, David J Nutt
Page
of 33